Starting July 1st, nearly 4 million Americans on Medicare can get GLP-1 weight-loss medications — drugs like Wegovy, Foundayo, and Zepbound — for a $50 monthly copay. The same prescriptions that cost between $149 and $449 out of pocket just became accessible to seniors who couldn't afford them.
That's not a pilot program. That's not a proposal. It's live.
CMS Administrator Dr. Mehmet Oz announced the Medicare GLP-1 Bridge on July 1st, calling it a direct delivery from the Trump administration's MAHA — Make America Healthy Again — initiative. "The Trump Administration is delivering big news in Medicare," Oz said. "Through the Medicare GLP-1 Bridge, eligible beneficiaries can access certain GLP-1 medications for weight management for just a $50 monthly copay."
The program targets Medicare Part D enrollees who don't already have GLP-1 coverage and meet specific clinical thresholds. The primary eligibility criterion is a BMI of 35 or over. Beneficiaries with a BMI between 27 and 30 can also qualify if they have additional medical conditions — a previous heart attack or uncontrolled high blood pressure, for example. According to analysis by KFF, the health policy research group, roughly 3.8 to 4 million Medicare beneficiaries fall into the eligible population.
The drugs themselves have been the most talked-about pharmaceutical development in years. Wegovy is available in both tablet and injection form. Foundayo comes as tablets. Zepbound Quikpens are injection-only. All of them are GLP-1 receptor agonists originally developed for diabetes management that turned out to produce significant weight loss — and the cash-pay prices have kept them out of reach for most people on fixed incomes.
Even CNN's reporting acknowledged the scale. One of their reporters called it "a REALLY BIG DEAL for many senior citizens and Medicare enrollees who have been waiting for years." When CNN concedes that a Trump-era health policy is a big deal, the actual impact is probably larger than anyone's admitting.
HHS Secretary Robert F. Kennedy Jr. has been pushing the MAHA agenda since taking the post, and Representative Tom Kean, Republican from New Jersey's 7th district, was among those flagging the announcement as a concrete policy win. The criticism from the other side has been notably thin — it's hard to argue against making life-changing medication affordable for seniors on Medicare.
The previous approach to GLP-1 coverage was essentially to wait. Wait for prices to come down. Wait for generics. Wait for Congress to pass something. Meanwhile, millions of seniors with obesity-related health conditions kept paying full freight or went without. The Medicare GLP-1 Bridge skipped the waiting and built the program through CMS rulemaking.
Here's what $50 a month means for a retired couple in Ohio on Medicare: it means the drug their doctor recommended six months ago is now something they can actually pick up at the pharmacy. It means the weight-related complications that were driving up their other medical costs might start going the other direction.
Four million people. Fifty dollars. Already in effect.
That's the kind of policy that doesn't need a press conference. It just needs a pharmacy counter.